An underground market for unapproved weight-loss medications is being driven by social media fitness personalities and vendors on messaging platforms, according to recent findings.
Investigational Treatment Gaining Traction Via Social Media
The experimental drug, which remains in clinical trials, is being promoted by online personalities for its supposed fat-burning effects. Viewers are urged to contact these profiles privately for supplier links, while also receiving discount codes.
Thriving Trade on Social Networks
Separately, a flourishing market exists on Telegram, where communities with thousands of members share comparison photos, administration instructions and claims of rapid UK delivery. Sellers market the drug there before redirecting customers to other platforms for transactions.
Learning About The Experimental Drug
This medication is an experimental injectable developed by US drugmaker Eli Lilly. The treatment targets three intestinal hormones – GLP-1, glucose-dependent insulinotropic polypeptide and glucagon. Early trials suggest it could assist individuals lose up to a quarter of their body weight. Referred to as the “triple G”, the drug is being hailed digitally as the successor to Ozempic.
Medical Experts Voice Worries
However, physicians and chemists have cautions that the distribution of what is still an unlicensed medication in the United Kingdom is a cause for concern and could lead to individuals injecting substances of uncertain source.
Several professionals said the popularity for the experimental drug could be linked to the increasing price of licensed weight loss products such as Mounjaro.
Legal Status and Enforcement
Selling the unapproved drug on social media or messaging apps is illegal in the UK, as it is an unlicensed drug that must not be marketed or distributed for human use under the Human Medicines Regulations 2012.
Several influencers attempt to circumvent the rules by calling to the substance as a “research chemical” or describing it as “not for human consumption”. The substance is not a controlled substance, but advertising and supply can still breach pharmaceutical, marketing, and consumer laws, risking penalties, legal action or prison.
Service Response and Content Removal
Based on the social media company, the platform has taken down violative content and banned associated hashtags and query recommendations. The company said it was dedicated to maintaining the platform safe and allocating resources in enhancing enforcement strategies.
Online Marketplace Activities
Research also found groups with up to nine thousand participants marketing the experimental drug using the platform's integrated search feature, which functions like a online catalog. Typing “retatrutide” instantly brings up groups with thousands of users, filled with images of slimming results, positive reviews and detailed instructions for preparing or administering at home.
Within moments of entering one community, a seller posted contact information, where the majority of transactions occur. The seller provided an instruction manual and guaranteed delivery within two days. When asked whether the product was genuine, one seller responded: “You can’t be sure.” Another provided a photo of a alleged testing documentation. None asked about body mass, medical conditions or past usage.
Item Information and Costs
Within these communities, posts show dark colored parcels with Royal Mail labels, claiming to include new batches. One communication stated: “It took eight of us to load them this morning.”
Customers can choose between dry substance containers, mixed at home with purified liquid, or ready-to-use pens usually sold at 160 pounds for 20 milligrams. When asked how long a injector should be used, vendors give conflicting responses ranging from a few weeks to “depends on your body”.
Service Moderation and Security Measures
A spokesperson for the messaging service said it actively moderated harmful material on its platform including content that promoted the “misuse of controlled medications”. The company noted that it removed “millions of pieces of harmful content each day”.
Healthcare Expert Warnings
“People are administering substances they cannot confirm. Even if the science behind retatrutide is valid, these digital versions may not contain what they advertise,” said a pharmacy expert, the director of pharmacy at a pharmacy service.
Dr Crystal Wyllie of Asda Online Doctor linked the increase in interest to recent cost increases for authorized slimming drugs such as Mounjaro. “With costs increasing, individuals are turning to social media. But counterfeit treatments are extremely dangerous. You cannot know what’s contained or whether the environment they were made in was clean,” she explained.
Her staff has previously encountered patients harmed by personal administration from unconfirmed sources. “We recognize the disappointment, but purchasing from Telegram or WhatsApp is gambling with your well-being,” stated Wyllie. “These substances could be contaminated or incorrectly dosed.”
Manufacturer Position
A representative from Eli Lilly stated retatrutide was in third stage research studies and had not been reviewed or approved by any regulatory agency globally. “Therefore at this time no one can sell [it] for personal consumption,” they said, adding that any product “falsely representing itself as a Lilly experimental product not yet approved … may expose patients to possibly significant medical dangers”.
